Related Experiment Video
Updated: May 31, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dronedarone for atrial fibrillation therapy
Michele Marzocchi1, Federico Lombardi
1Cardiologia, DMCO Osp. San Paolo, University of Milan, Via A. di Rudinì 8, 20142 Milan, Italy.
Expert Review of Cardiovascular Therapy
|July 1, 2011
Summary
Dronedarone, a new antiarrhythmic drug, offers similar effects to amiodarone but with reduced toxicity. Clinical trials show it
Area of Science:
- Pharmacology
- Cardiology
- Medicinal Chemistry
Background:
- Dronedarone is a benzofuran derivative designed to mimic amiodarone's antiarrhythmic effects.
- The development aimed to reduce amiodarone's associated thyroid and pulmonary toxicity.
Purpose of the Study:
- To evaluate dronedarone as an antiarrhythmic agent.
- To compare its efficacy and safety profile against amiodarone.
Main Methods:
- Dronedarone acts as a multichannel blocker with antiadrenergic properties.
- Pharmacokinetic studies indicate primary metabolism by cytochrome P450 and a shorter half-life due to lower lipophilicity.
- Clinical trials assessed its use in rate and rhythm control for atrial fibrillation.
Main Results:
- Dronedarone reduces heart rate and prolongs action potential duration.
- Steady-state plasma levels are achieved within 7 days.
- While potentially less potent than amiodarone, dronedarone shows a lower discontinuation rate due to adverse reactions and toxicity.
Conclusions:
- Dronedarone is a viable option for long-term atrial fibrillation management.
- It effectively reduces hospitalizations and mortality in patients with atrial fibrillation.
- Its improved safety profile makes it a valuable alternative to amiodarone.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...